MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2

Yao,Qiang; Gu,Anxin; Wang,Zhuozhong; Xue,Yingwei

doi:10.3892/etm.2018.5763

MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2

Authors:
- Qiang Yao
- Anxin Gu
- Zhuozhong Wang
- Yingwei Xue
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China, Department of Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China, Department of Statistics, Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China
Published online on: January 17, 2018 https://doi.org/10.3892/etm.2018.5763
Pages: 3088-3095

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) poses a serious public health threat and the 5‑year survival rate of patients with GC is low. MicroRNAs (miRNAs/miRs) may serve oncogenic or tumor suppressor functions during tumorigenesis by regulating cell proliferation, apoptosis, migration and invasion and it has been demonstrated that they may be dysregulated in various types of cancer. The present study demonstrated that miR‑144 and GATA4 were downregulated in GC tissues and cell lines and suggested that this may be due to hypermethylation. Additionally, miR‑144 and GATA4 had synergistic effects on GC cells by repressing cell proliferation and inducing cell cycle arrest and apoptosis. The results of bioinformatics and a luciferase reporter assay indicated that cyclooxygenase‑2 (COX‑2) is a direct target of miR‑144 and that miR‑144 negatively regulated the expression of COX‑2, which inhibits the viability of GC cells. GATA4 also induced a similar effect on COX‑2. Taken together, the results of the present study may improve understanding of the underlying mechanism of miR‑144 and GATA4 in GC.

View Figures

View References

1	Heise K, Bertran E, Andia ME and Ferreccio C: Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol. 15:1854–1862. 2009. View Article : Google Scholar : PubMed/NCBI
2	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006. View Article : Google Scholar : PubMed/NCBI
3	Shi C, Liu B, Yan J, Liu H, Pan Z, Yao W, Yan F and Zhang H: Gastric cancer: Preoperative TNM staging with individually adjusted computed tomography scanning phase. J Comput Assist Tomogr. 40:160–166. 2016. View Article : Google Scholar : PubMed/NCBI
4	Hu B, El Hajj N, Sittler S, Lammert N, Barnes R and Meloni-Ehrig A: Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 3:251–261. 2012.PubMed/NCBI
5	Smyth EC and Cunningham D: Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology. Nat Rev Clin Oncol. 10:73–74. 2013. View Article : Google Scholar : PubMed/NCBI
6	Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K and Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands. Eur J Cancer. 46:1101–1110. 2010. View Article : Google Scholar : PubMed/NCBI
7	Wu CW, Lo SS, Shen KH, Hsieh MC, Lui WY and P'eng FK: Surgical mortality, survival and quality of life after resection for gastric cancer in the elderly. World J Surg. 24:465–472. 2000. View Article : Google Scholar : PubMed/NCBI
8	Yalçin S: The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointest Cancer Res. 3:197–203. 2009.PubMed/NCBI
9	Melo SA and Esteller M: Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wang YY, Li L, Ye ZY, Zhao ZS and Yan ZL: MicroRNA-10b promotes migration and invasion through Hoxd10 in human gastric cancer. World J Surg Oncol. 13:2592015. View Article : Google Scholar : PubMed/NCBI
11	Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 34:537–542. 2009.PubMed/NCBI
12	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional links between clustered microRNAs: Suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
14	Li X, Zhang Y, Shi Y, Dong G, Liang J, Han Y, Wang X, Zhao Q, Ding J, Wu K and Fan D: MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med. 15:1887–1895. 2011. View Article : Google Scholar : PubMed/NCBI
15	Jiang H, Yu WW, Wang LL and Peng Y: miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncol Rep. 34:1153–1161. 2015. View Article : Google Scholar : PubMed/NCBI
16	Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, Chen L, Pang X, Leng W and Bi F: Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 31:1863–1870. 2014. View Article : Google Scholar : PubMed/NCBI
17	Meder B, Backes C, Haas J, Leidinger P, Stähler C, Großmann T, Vogel B, Frese K, Giannitsis E, Katus HA, et al: Influence of the confounding factors age and sex on microRNA profiles from peripheral blood. Clin Chem. 60:1200–1208. 2014. View Article : Google Scholar : PubMed/NCBI
18	Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y and Kusunoki M: Circulating microRNA-203 predicts metastases, early recurrence and poor prognosis in human gastric cancer. Gastric Cancer. 19:744–753. 2016. View Article : Google Scholar : PubMed/NCBI
19	Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, Sasako M, Maehara Y, Mimori K and Mori M: Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer. 107:1345–1353. 2012. View Article : Google Scholar : PubMed/NCBI
20	Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, Ma J, Cai D and Gu X: MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 34:352015. View Article : Google Scholar : PubMed/NCBI
21	Grépin C, Nemer G and Nemer M: Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development. 124:2387–2395. 1997.PubMed/NCBI
22	Zhang X, Wang X, Zhu H, Zhu C, Wang Y, Pu WT, Jegga AG and Fan GC: Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol. 49:841–850. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yin J, Liu B, Li B, Liu Z, Xie X, Lv Z, Gao S and Guang J: The cyclooxygenase-2 inhibitor celecoxib attenuates hepatocellular carcinoma growth and c-Met expression in an orthotopic mouse model. Oncol Res. 19:131–139. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, Tian DA and Zhang P: MicroRNA143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol. 19:7758–7765. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wang Z, Chen JQ and Liu JL: COX-2 inhibitors and gastric cancer. Gastroenterol Res Pract. 2014:1323202014. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Lynch J, Meehan MH, Crean J, Copeland J, Stallings RL and Bray IM: Metastasis suppressor microRNA-335 targets the formin family of actin nucleators. PLoS One. 8:e784282013. View Article : Google Scholar : PubMed/NCBI
28	Ma J, Hong L, Chen Z, Nie Y and Fan D: Epigenetic regulation of microRNAs in gastric cancer. Dig Dis Sci. 59:716–723. 2014. View Article : Google Scholar : PubMed/NCBI
29	Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D, Wang L, Wang YJ, Zong Y, Wu YD and Zhang ST: MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget. 7:15173–15186. 2016. View Article : Google Scholar : PubMed/NCBI
30	Hsu KW, Hsieh RH, Huang KH, Fen-Yau Li A, Chi CW, Wang TY, Tseng MJ, Wu KJ and Yeh TS: Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression. Carcinogenesis. 33:1459–1467. 2012. View Article : Google Scholar : PubMed/NCBI
31	Yu JW, Wu JG, Zheng LH, Zhang B, Ni XC, Li XQ and Jiang BJ: Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma. J Exp Clin Cancer Res. 28:552009. View Article : Google Scholar : PubMed/NCBI
32	Tsai MM, Wang CS, Tsai CY, Huang HW, Chi HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and therapeutic targets of MicroRNAs in human gastric cancer. Int J Mol Sci. 17:E9452016. View Article : Google Scholar : PubMed/NCBI
33	Hersey P and Zhang XD: Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunol Immunother. 58:1749–1759. 2009. View Article : Google Scholar : PubMed/NCBI
34	Xiao B, Guo J, Miao Y, Jiang Z, Huan R, Zhang Y, Li D and Zhong J: Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta. 400:97–102. 2009. View Article : Google Scholar : PubMed/NCBI
35	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
36	Zhang Z, Kong Y, Yang W, Ma F, Zhang Y, Ji S, Ma EM, Liu H, Chen Y and Hua Y: Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep. 36:2361–2397. 2016.
37	Song B, Yan J, Liu C, Zhou H and Zheng Y: Tumor suppressor role of miR-363-3p in gastric cancer. Med Sci Monit. 21:4074–4080. 2015. View Article : Google Scholar : PubMed/NCBI
38	Li D, Li Z, Xiong J, Gong B, Zhang G, Cao C, Jie Z, Liu Y, Cao Y, Yan Y, et al: MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression. Am J Cancer Res. 5:2980–2997. 2015.PubMed/NCBI
39	Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, Kawabata M, Fujisawa M, Nibu K and Shirakawa T: In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer. 105:393–402. 2011. View Article : Google Scholar : PubMed/NCBI
40	Elmets CA, Ledet JJ and Athar M: Cyclooxygenases: Mediators of UV-induced skin cancer and potential targets for prevention. J Invest Dermatol. 134:2497–2502. 2014. View Article : Google Scholar : PubMed/NCBI